{"entity":{"id":"nct06459869","kind":"trial","name":"NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","aka":[],"tldr":"A phase 1 trial of NG-350A run by Akamis Bio, active, not recruiting.","summary":"NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer is a phase 1 interventional study registered as NCT06459869 by Akamis Bio, with 33 participants planned, started 2025-04-07, primary completion expected 2027-01-30. Conditions recorded: Locally Advanced Rectal Cancer (LARC). Interventions recorded: NG-350A IV administration, Capecitabine oral administration, Radiotherapy.","status":"active","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT06459869","url":"https://clinicaltrials.gov/study/NCT06459869"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ng-350a"],"companies":["akamis-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06459869","phase":"1","setting":"A Multicentre, Open-label, Non-randomized, Phase 1b Trial of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Chemoradiotherapy in Locally Advanced Rectal Cancer (FORTRESS)","sponsor":"Akamis Bio","enrolled":33,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06459869/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"drug":[{"id":"ng-350a","kind":"drug","name":"NG-350A","route":"/drugs/ng-350a/"}],"company":[{"id":"akamis-bio","kind":"company","name":"Akamis Bio","route":"/companies/akamis-bio/"}]}}